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Abstract
Background:  Human immunodeficiency virus type 1 (HIV-1) infection and the consequent acquired
immunodeficiency syndrome (AIDS) has protean manifestations, including muscle wasting and cardiomyopathy,
which contribute to its high morbidity. The pathogenesis of these myopathies remains partially understood, and
may include nutritional deficiencies, biochemical abnormalities, inflammation, and other mechanisms due to viral
infection and replication. Growing evidence has suggested that HIV-1-related proteins expressed by the host in
response to viral infection, including Tat and gp120, may also be involved in the pathophysiology of AIDS,
particularly in cells or tissues that are not directly infected with HIV-1. To explore the potentially independent
effects of HIV-1-related proteins on heart and skeletal muscles, we used a transgenic rat model that expresses
several HIV-1-related proteins (e.g., Tat, gp120, and Nef). Outcome measures included basic heart and skeletal
muscle morphology, glutathione metabolism and oxidative stress, and gene expressions of atrogin-1, muscle ring
finger protein-1 (MuRF-1) and Transforming Growth Factor-β1 (TGFβ1), three factors associated with muscle
catabolism.
Results: Consistent with HIV-1 associated myopathies in humans, HIV-1 transgenic rats had increased relative
heart masses, decreased relative masses of soleus, plantaris and gastrocnemius muscles, and decreased total and
myosin heavy chain type-specific plantaris muscle fiber areas. In both tissues, the levels of cystine (Cyss), the
oxidized form of the anti-oxidant cysteine (Cys), and Cyss:Cys ratios were significantly elevated, and cardiac tissue
from HIV-1 transgenic rats had altered glutathione metabolism, all reflective of significant oxidative stress. In HIV-
1 transgenic rat hearts, MuRF-1 gene expression was increased. Further, HIV-1-related protein expression also
increased atrogin-1 (~14- and ~3-fold) and TGFβ1 (~5-fold and ~3-fold) in heart and plantaris muscle tissues,
respectively.
Conclusion: We provide compelling experimental evidence that HIV-1-related proteins can lead to significant
cardiac and skeletal muscle complications independently of viral infection or replication. Our data support the
concept that HIV-1-related proteins are not merely disease markers, but rather have significant biological activity
that may lead to increased oxidative stress, the stimulation of redox-sensitive pathways, and altered muscle
morphologies. If correct, this pathophysiological scheme suggests that the use of dietary thiol supplements could
reduce skeletal and cardiac muscle dysfunction in HIV-1-infected individuals.
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Background
Although infection with the human immunodeficiency
virus type 1 (HIV-1) is more commonly associated with
serious derangements to the central nervous, pulmonary,
and lymphatic systems, the acquired immunodeficiency
syndrome (AIDS) can also produce significant cardiac and
skeletal muscle dysfunction. For example, HIV-1-related
cardiomyopathies may include left ventricular dysfunc-
tion, dilatation, and heart failure [1]. Further, skeletal
muscle derangements due to HIV-1 infection may include
polymyositis, rhabdomyolysis, tumor infiltrations, wast-
ing syndromes, severe weakness, and fatigue [2,3].
The pathogenesis of HIV-1-associated myopathies is not
fully understood, but has been attributed in part to poor
nutritional states, elevated cytokine levels, oxidative
stress, and other mechanisms associated with viral infec-
tion and replication [2,4,5]. Interestingly, evidence has
evolved implicating HIV-1-related proteins, including
gp120 and Tat, as mediators of injury even when target
cells are not directly infected with HIV-1 [6-10]. For exam-
ple, elevated levels of HIV-1 RNA in plasma correlate with
decreased skeletal muscle amino acid metabolism and
protein synthesis rates [6]. HIV-1 transcripts have also
been detected in a small number of myocardial cells [7];
and the targeted expression of HIV-1 Tat in mouse hearts
resulted in significant oxidative stress and severe myocar-
dial derangements suggesting a predominant role of oxi-
dative stress in HIV-1-related cardiomyopathies [8].
However, the influence of HIV-1-related protein-induced
oxidative stress on specific redox-sensitive mechanisms in
cardiac and skeletal muscle tissues remains largely
unknown.
We have recently shown that two catabolic factors,
atrogin-1 and Transforming Growth Factor-β1 (TGFβ1),
are sensitive to oxidative stress in skeletal muscles from
alcohol-fed rats [11]. Based on these observations and
strong evidence that HIV-1 is also associated with
increased oxidative stress [12], the aim of the current
study was to determine the potential roles these redox-
sensitive factors may play in HIV-1 myopathies. In addi-
tion, we analyzed the expression levels of muscle ring fin-
ger protein-1 (MuRF-1); that, like atrogin-1, is a muscle
specific E3 ligase implicated in muscle atrophy [13]. Tak-
ing advantage of a non-replicative, non-infectious HIV-1
transgenic rat model [14], we show that chronic expres-
sion of HIV-1-related proteins causes significant cardiac
and skeletal muscle morphological derangements includ-
ing increased relative heart masses and muscle atrophy.
These derangements may be due in part to increased oxi-
dative stress, with particular alterations to glutathione
metabolism, and increased expressions of atrogin-1,
MuRF-1 and TGFβ1.
Results
Gross pathology of HIV-1 transgenic rats
Preliminary data showed that heart and skeletal muscle
tissues from young HIV-1 transgenic rats (e.g., 2–4
months) do not exhibit any HIV-1 related defects in mor-
phology. These initial observations are in agreement with
those of Reid and colleagues that suggested HIV-1 associ-
ated complications in these transgenic rats manifest
between 5–9 months of age [14]. We now show that 7
month old HIV-1 transgenic rats also have significantly
larger relative heart masses, atrophied gastrocnemius,
soleus and plantaris muscles (Fig. 1A), and decreased total
and MHC-specific plantaris fiber areas (Fig. 1B).
Oxidative stress in muscle tissues from HIV-1 transgenic 
rats
HIV-1 infection is associated with increased oxidative
stress [5]. Therefore, we next identified the effect of HIV-
1-related protein expression on the glutathione (GSH)
anti-oxidant system in heart and plantaris muscles. In
heart tissues, no effects of the transgene were evident on
the levels of GSH or glutathione disulfide (GSSG) (Fig. 2A
and 2B, respectively). However, the GSSG:GSH ratio, a
marker of the oxidative state of the GSH pool, was signif-
icantly elevated in heart tissues from HIV-1 transgenic rats
(Fig. 2C) suggesting increased oxidative stress to this thiol
pool. Heart tissues from HIV-1 transgenic rats also had
significantly lower levels of cysteine (Cys), higher levels of
cystine (Cyss), and an elevated Cyss:Cys ratio (Fig. 2D–F,
respectively). Interestingly, both GSH and GSSG level
were increased in plantaris muscles from HIV-1transgenic
rats compared to controls (Fig. 3A and 3B, respectively).
However, there was no difference in the GSSG:GSH ratio
between these groups suggesting that the GSH pool was
largely unaffected by the products of the transgene (Fig.
3C). In contrast, plantaris muscles from HIV-1 transgenic
rats had increased Cyss levels and an increased Cyss:Cys
ratio suggesting significant oxidative stress to this thiol
pool (Fig. 3E and 3F, respectively).
Atrogin-1, Muscle ring finger protein-1 (MuRF-1), and 
Transforming Growth Factor-β1 (TGFβ1) expressions
Using a model of chronic alcohol ingestion to induce oxi-
dative stress in skeletal muscle, we have recently identified
atrogin-1 and TGFβ1 as redox-sensitive catabolic factors
[11]. However, whether or not these factors or MuRF-1
were also sensitive to HIV-1-related protein-induced oxi-
dative stress was unknown. Atrogin-1 levels increased
~14- and ~3-fold in heart and plantaris muscles from HIV-
1 transgenic rats, respectively (Figures 4A and 4D). Inter-
estingly, MuRF-1 mRNA levels were only increased in
HIV-1 transgenic rat hearts (Figure 4B). Gene levels of
TGFβ1  were increased ~5- and ~3-fold in heart and
plantaris muscles from HIV-1 transgenic rats, respectively
(Figures 4C and 4F).AIDS Research and Therapy 2008, 5:8 http://www.aidsrestherapy.com/content/5/1/8
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Discussion
In this study, we examined two muscle types from HIV-1
transgenic rats and report significant morphological
derangements, including increased relative heart weights,
decreased relative masses of the plantaris, soleus and gas-
trocnemius, and plantaris fiber atrophy. In both tissue
types, these effects were associated with increased oxida-
tive stress, as reflected by alterations in the cysteine and
glutathione redox balances. In parallel, we determined
that HIV-1-related protein expression alone, in complete
absence of viral replication and infection, is sufficient to
induce atrogin-1 and TGFβ1 gene expressions, two factors
strongly implicated in muscle catabolism. We also
showed that the E3 ubiquitin ligase, MuRF-1, was signifi-
Gross pathology of heart and plantaris muscles from HIV-1 transgenic rats Figure 1
Gross pathology of heart and plantaris muscles from HIV-1 transgenic rats. (A) Relative heart masses from HIV-1 
transgenic rats were increased compared to controls. In addition to this cardiac tissue defect, several skeletal muscles from 
HIV-1 transgenic rats were atrophied, including gastrocnemius (gastroc), soleus, and plantaris. (B) Specifically, the cross-sec-
tional areas (CSA) of total and myosin heavy chain (MHC) isoform type-specific (i.e., slow, hybrid or fast MHC isoforms) from 
plantaris fibers were reduced in HIV-1 transgenic rats. Data in panel A represented as milligram of tissue weight divided by 
body mass in grams. Bar in panel B = 100 μm. *, p ≤ 0.05 vs. control.AIDS Research and Therapy 2008, 5:8 http://www.aidsrestherapy.com/content/5/1/8
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cantly upregulated in HIV-1 transgenic rat hearts.
Together, these data suggest an important and previously
unrecognized relationship in HIV-1 myopathies between
the bioactivity of HIV-related proteins and oxidative
stress-mediated signaling events. These findings may also
suggest that dietary anti-oxidant therapy with thiols such
as S-adenosyl-methionine, N-acetylcysteine, or pro-
cysteine may reduce the influences of oxidative stress and/
or redox-sensitive signaling pathways in HIV-1-infected
individuals.
HIV-1 infection leads to impaired antigen-specific T cell
proliferation and heightened susceptibility to apoptosis.
Similarly, HIV-1 transgenic rats, despite the absence of
characteristic viral disease progression, have an absolute
reduction in CD4+, a reduced number of IFN-gamma-
GSH and Cys pools in heart tissues from HIV-1 transgenic rats Figure 2
GSH and Cys pools in heart tissues from HIV-1 transgenic rats. High performance liquid chromatography was per-
formed on heart tissues to detect levels of the thiol pairs GSH and GSSG, and Cys and Cyss. HIV-1-related protein expression 
had no effect on GSH or GSSG levels (A and B), but did increase the overall oxidative state of the GSH pool (C). In contrast, 
Cys levels were reduced and Cyss levels were elevated in heart tissues from HIV-1 transgenic rats compared to controls (D 
and E, respectively). Therefore, the Cyss:Cys ratio, a marker of the overall oxidative state of the Cys pool, was significantly 
increased in HIV-1 transgenic rat hearts (F). *, p ≤ 0.05 vs. control.AIDS Research and Therapy 2008, 5:8 http://www.aidsrestherapy.com/content/5/1/8
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producing CD8+ T cells, and an increased susceptibility of
T cells to activation-induced apoptosis [15]. Likewise,
HIV-1 transgenic rats develop many clinical manifesta-
tions by 5–9 months of age that resemble AIDS, including
neurological abnormalities, mild interstitial pneumonia,
and endocarditis [14]. We now show that HIV-1 trans-
genic rats also have increased relative heart weights and
significant skeletal muscle atrophy – consistent with car-
diac and skeletal myopathies seen in individuals with
AIDS. For example, reports have suggested extensive left
ventricular hypertrophy and elevated heart weights in
HIV-1-infected children [16]. Further, HIV-1-infected
individuals may present with significant loss of lean body
mass, skeletal muscle wasting, and concomitant reduc-
GSH and Cys pools in plantaris muscles from HIV-1 transgenic rats Figure 3
GSH and Cys pools in plantaris muscles from HIV-1 transgenic rats. High performance liquid chromatography was 
performed on plantaris muscles to detect levels of the thiol pairs GSH and GSSG, and Cys and Cyss. HIV-1-related protein 
expression increased the levels of GSSG (B) and Cyss (E) compared to controls. Surprisingly, GSH levels were markedly 
increased in plantaris muscles from HIV-1 transgenic rats (A), which served to normalize the overall oxidative state of the GSH 
pool (C). In contrast, the overall oxidative state of the Cys pool was significantly increased in HIV-1 transgenic rat plantaris 
muscles (F). *, p ≤ 0.05 vs. control.AIDS Research and Therapy 2008, 5:8 http://www.aidsrestherapy.com/content/5/1/8
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Atrogin-1, MuRF-1 and TGFβ1 mRNA expression patterns in cardiac and plantaris tissues from HIV-1 transgenic rats Figure 4
Atrogin-1, MuRF-1 and TGFβ1 mRNA expression patterns in cardiac and plantaris tissues from HIV-1 trans-
genic rats. Gene expression levels of several catabolic factors including, atrogin-1, MuRF-1 and TGFβ1, were markedly 
increased in HIV-1 transgenic rat heart tissues compared to controls (A-C, respectively). Similarly, mRNA expression levels of 
atrogin-1 and TGFβ1 were increased in plantaris muscles from HIV-1 transgenic rats compared to controls (D and F, respec-
tively), however, no changes were detected in the levels of MuRF-1 (E). *, p ≤ 0.05 vs. control.AIDS Research and Therapy 2008, 5:8 http://www.aidsrestherapy.com/content/5/1/8
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tions in functional capacity [2,3,17]. In this experimental
study, plantaris fiber atrophy was apparent in both fast
and slow myosin heavy chain (MHC) fiber types in HIV-1
transgenic rats. Further, soleus and gastrocnemius muscles
were atrophied in these transgenic rats (data not shown)
suggesting that HIV-1-related protein expression induces
systemic atrophy that is neither fiber-type nor muscle-type
specific. Interestingly, our data are in contrast to a recent
report that showed type II fiber-specific atrophy in exten-
sor digitorum longus (EDL) and gastrocnemius muscles
with preserved type I fiber area in soleus muscles from a
transgenic mouse model of HIV-1 (i.e., "Tg26") [17]. We
did not distinguish between the fast subtypes of MHC iso-
forms found in rats (i.e., types IIa, IIx, and IIb) and while
diffuse atrophy has been reported here and in the litera-
ture [18], the subtle morphological and genetic differ-
ences between the mouse and rat transgenic models and
the stage of disease progression may account for the dis-
crepancies with the current work. Nevertheless, both stud-
ies confirm that HIV-1-related proteins have significant
biological activity and induce systemic muscle atrophy.
We next identified the effect of HIV-1-related protein
expression on oxidative stress and redox balance. Oxida-
tive stress is a common complication in HIV-1-infected
individuals and is likely responsible, at least in part, for
cardiac and skeletal muscle myopathies [19]. Here, we
show that both muscle types experience significant oxida-
tive stress, with specific detriments to components of the
GSH anti-oxidant cycle. Importantly, previous work has
suggested that GSH replacement therapies using precur-
sors such as L-glutamine in HIV-1-infected individuals
successfully replenishes the available pool of GSH and
preserves lean body mass [20]. Further, in combination
with traditional highly active antiviral therapies (HAART),
the adjunctive use of nutritional therapies like N-acetyl
cysteine or α-lipoic acid supplementation may interrupt
the process of viral activation and CD4 cell death [5,21].
Therefore, the inclusion of GSH replacement strategies in
the treatment regimes of HIV-1-infected individuals may
be warranted in order to reduce oxidative stress and possi-
bly attenuate muscle catabolism. Based on our previous
associations between alcohol-induced oxidative stress and
atrogin-1 and TGFβ1expressions, GSH supplementation
in HIV-1-infected individuals may have the added benefit
of attenuating redox-sensitive mechanisms implicated in
cardiac and skeletal muscle derangements [11].
Atrogin-1, also known as Muscle Atrophy F-box (MAFbx),
and muscle ring finger protein-1 (MuRF-1) are E3 ubiqui-
tin ligase that initiates ATP-dependent, ubiquitin-medi-
ated proteolysis and are abundant in skeletal muscles
undergoing atrophy [13,22]. However, the roles of these
atrophy-related genes, or atrogenes [23], in the regulation
of cardiac mass is more controversial. For example,
atrogin-1 inhibited pathologic cardiac hypertrophy by ini-
tiating the degradation of calcineurin, a calcium-depend-
ent phosphatase implicated in pathologic hypertrophy
[24]. Further, both genes were decreased in unloading-
induced cardiac atrophy [25]. In contrast, atrogin-1
mRNA levels were increased in hypertrophied rat hearts
[26]. Here, both muscle types showed increased mRNA
levels of atrogin-1 suggesting that this ubiquitin ligase
plays an important role in regulating these defects. In sup-
port of this notion, skeletal muscles from cachectic, HIV-
1-infected individuals showed a dramatic increase in the
gene levels of 2.4 and 1.2 kb ubiquitin, and the C8 protea-
some [27].
A recent report suggested that atrogin-1 may regulate
TGFβ signaling by degrading specific substrates associated
with this pathway [28]. TGFβ is a superfamily of pluripo-
tent cytokines implicated in skeletal muscle catabolic con-
ditions and in the development of cardiac fibrosis [29,30].
Interstitial and myocardial fibrosis has been reported in
HIV-infected patients [31,32], and while we did not
directly test for the presence of myocardial fibrosis, gene
levels of the pro-fibrotic cytokine TGFβ1 were significantly
upregulated in the hearts of transgenic rats. Further, in
light of the evolving evidence implicating atrogin-1 and
TGFβ1 in the pathophysiology of these muscle derange-
ments, our findings suggest a mechanistic relationship
between HIV-1-induced oxidative stress and these cata-
bolic mechanisms. Taken together, our data support the
hypothesis that these redox-sensitive inductions of cata-
bolic factors by HIV-1-related proteins represent signifi-
cant clinical alterations in the evolution of HIV-1
myopathies that are responsible, at least in part, for the
establishment of a catabolic signaling milieu.
Conclusion
Using a unique HIV-1 transgenic rat model, we provide
compelling experimental evidence that HIV-1-related pro-
tein expression, in the absence of viral replication, is suf-
ficient to reproduce many clinical manifestations
commonly described in the human condition, including
increased heart mass, skeletal muscle atrophy and oxida-
tive stress. These muscle derangements may be due in part
to specific alterations in redox-sensitive thiols including
cysteine and glutathione. We also determined that heart
and plantaris muscles from HIV-1 transgenic rats have
increased levels of the redox-sensitive catabolic factors.
Therefore, if this pathophysiological scheme identified in
this HIV-1 transgenic model proves to be relevant to the
human condition, this study suggests that dietary supple-
mentation with cysteine or other glutathione precursors
could modulate oxidative stress and/or redox-sensitive
signaling events and decrease skeletal and cardiac myopa-
thy in HIV-1-infected individuals.AIDS Research and Therapy 2008, 5:8 http://www.aidsrestherapy.com/content/5/1/8
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Methods
Animals and tissue collections
Male, Fischer 344/NHsd HIV-1 transgenic rats
(hemizygous NL4-3Δgag/pol) [14] and wild type Fischer
344/NHsd rats (~400 g, n = 6/group) were purchased
from Harlan (Indianapolis, Indiana) and housed in pairs
under a 12:12 light-dark cycle. Animals had free access to
food and water. All procedures were approved by Atlanta
Veteran Affairs Medical Center Institutional Animal Care
and Use Committee.
Rats were anesthetized with sodium pentobarbital, heart
and plantaris muscles were removed, blotted dry, weighed
and prepared for further analyses. For measures involving
heart tissue, ventricles were separated from atria and used
for all experiments.
Plantaris morphology & MHC isoform expression
Plantaris muscles were embedded in OCT and immedi-
ately frozen in isopentane cooled in liquid nitrogen. Serial
sections from the mid-belly of the plantaris muscle were
cut at 14 or 8 μm for analyses of CSA or MHC isoform
determination, respectively. All incubations were per-
formed at room temperature. For CSA determination,
plantaris sections were adhered to superfrost slides, proc-
essed for hematoxylin and eosin staining, dehydrated and
mounted. For MHC isoform determination, sections were
processed for immunohistochemical detection of slow or
fast MHC protein expression using the ABC method (Vec-
tor Labs, Burlingame, California). Sections were rehy-
drated in phosphate buffered saline (PBS, pH 7.4),
incubated in blocking solution for 20 min, and then incu-
bated in anti-slow MHC or anti-fast MHC IgG (Sigma, St.
Louis, Missouri) for 90 min. Sections were washed in PBS,
incubated in biotinylated secondary antibody for 60 min,
washed again in PBS, and then incubated in an avidin-rich
solution for 60 min. After a final wash, positive biotin-avi-
din binding was observed with diaminobenzidine. All sec-
tions were visualized with a Leica microscope and
measured using ImageJ software (NIH, Bethesda, Mary-
land). Approximately 125 fibers per muscle were ana-
lyzed. Data are expressed as the percentage of slow (type
I), hybrid (co-expression of types I and II), and fast (type
II) MHC types relative to the total pool of MHC isoforms.
High performance liquid chromatography
For determining the levels of GSH, GSSG, Cys, and Cyss in
heart and plantaris muscle tissues, we used a variation of
the high performance liquid chromatography (HPLC)
method previously described [11]. Briefly, each sample
was extracted in 5% perchloric acid with 0.2 M boric acid
and 10 μM γ-glutamyl-glutamate as an internal standard.
Iodoacetic acid was added and the pH was adjusted to 9.0
± 0.2. After incubation for 20 min to obtain S-carboxyme-
thyl derivatives of thiols, dansyl chloride was added and
the samples were incubated for 24 h in the dark. Samples
were then separated on an amine column with solvents
previously described [11]. Fluorescence detection was
used for separation and quantification of the dansyl deriv-
atives. The redox pairs (i.e., GSH and GSSG, Cys and Cyss)
were measured in parallel and expressed as picomoles per
milligram of plantaris tissue.
Real-time polymerase chain reaction (RT-PCR)
Heart and plantaris samples were immediately frozen in
liquid nitrogen and stored at -80°C until processed for
RT-PCR analyses. Trizol was added (1 ml/100 mg tissue)
and the tissues homogenized using an electric tissue
homogenizer. Total RNA (2.5 μg) was reverse transcribed
in a 40 μl final reaction volume using random primers
and M-MLV reverse transcriptase (Invitrogen, Carlsbad,
California). The reverse transcription reaction was incu-
bated at 65°C for 10 min, 80°C for 3 min, and 42°C for
60 min. RT-PCR products were analyzed using the iCycler
iQ system (Biorad, Hercules, California). cDNA (5 μl of a
1:10 dilution) was amplified in a 25 μl reaction contain-
ing 400-nm gene-specific primer pair and iQ Sybr Green
Supermix (Biorad). Primers were as follows: atrogin-1, 5'-
TCCAGACCCTCTACACATCCTT-3' and 5'-CCTCTGCAT-
GATGTTCAGTTGT-3'; MuRF-1, 5'-ATCACTCAGGAG-
CAGGAGGA-3' and 5'-CTTGGCACTCAAGAGGAAGG-3';
TGFβ1, 5'-CTACTACGCCAAAGAAGTCACC-3' and 5'-
CTGTATTCCGTCTCCTTGGTT-3'. Samples were incu-
bated at 95°C for 15 min, followed by 40 cycles of dena-
turation, annealing, and extension at 95°C, 60°C, and
72°C, respectively. As a control, RT-PCR was also per-
formed on 2 μl of each RNA sample to confirm absence of
contaminating genomic DNA. Fluorescence was recorded
at the end of each annealing and extension step. All reac-
tions were performed in triplicate and the starting quan-
tity of the gene of interest was normalized to 18S rRNA for
each sample. The delta-delta Ct method was used to ana-
lyze alterations in gene expression and values were
expressed as fold changes relative to control [11].
Statistics
Student's t-tests were performed to analyze differences
between HIV-1 transgenic and control rats. Significance
was accepted at p ≤ 0.05.
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